Junping Guo

Junping Guo


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2024 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
YZYingjie Zhang
Yingjie Zhang
CJChengkang Jin
Chengkang Jin
XXXiao-Ling Xu
Xiao-Ling Xu
JGJunping Guo
Junping Guo
LWLijun Wang
Lijun Wang
Misfolding and aggregation of specific proteins are associated with liquid-liquid phase separation (LLPS), and these protein aggregates can interfere with normal cellular functions and even lead to cell death, possibly affecting gene expression regulation and cell proliferation. Therefore, understanding the role of LLPS in disease may help to identify new mechanisms or therapeutic targets and provide new strategies for disease treatment. There are several ways to disrupt LLPS, including screening small molecules or small molecule drugs to target the upstream signaling pathways that regulate the LLPS process, selectively dissolve and destroy RNA droplets or protein aggregates, regulate the conformation of mutant protein, activate the protein degradation pathway to remove harmful protein aggregates. Furthermore, harnessing the mechanism of LLPS can improve drug development, including preparing different kinds of drug delivery carriers (microneedles, nanodrugs, imprints), regulating drug internalization and penetration behaviors, screening more drugs to overcome drug resistance and enhance receptor signaling. This review initially explores the correlation between aberrant LLPS and disease, highlighting the pivotal role of LLPS in preparing drug development. Ultimately, a comprehensive investigation into drug-mediated regulation of LLPS processes holds significant scientific promise for disease management.

1 July 2025 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
LCLu Chen
Lu Chen
RPRan Pan
Ran Pan
XXXiao-Ling Xu
Xiao-Ling Xu
JGJunping Guo
Junping Guo
Lipopolysaccharide (LPS) is a unique component of the outer wall of gram-negative bacteria and is a complex composed of lipids and polysaccharides. Normally, liver sinusoidal endothelial cells (LSECs) systemically clear LPS via unknown mechanisms. However, under pathological conditions, LPS causes lethal endotoxemia if it cannot be rapidly cleared from the blood circulation. Currently, an increasing number of drugs have demonstrated the ability to clear or neutralize LPS. However, due to their inherent characteristics, such as low biocompatibility and short half-life, their clinical applications are limited. Nanodrug delivery systems have the advantages of improving pharmacokinetics, increasing bioavailability, reducing the occurrence of side effects, and prolonging drug circulation time, which can compensate for the shortcomings of traditional drugs. This review summarizes nanodrug delivery systems that can clear or neutralize LPS, such as polymer nanodrug delivery systems, lipid-based nanodrug delivery systems, peptide-based nanodrug delivery systems, inorganic nanodrug delivery systems, nanosponges, and extracellular vesicles, which provides an outlook on the application and future prospects of nanodrug delivery systems for clearing and neutralizing LPS.

1 January 2024 in BIOCELL
Verified
Journal Article
Open access
PDF file
RPRan Pan
Ran Pan
JMJiayan Mao
Jiayan Mao
YZYueliang Zheng
Yueliang Zheng
WCWei Chen
Wei Chen
JGJunping Guo
Junping Guo
LWLijun Wang
Lijun Wang
Background: Sepsis, a type of systemic disease, can impact nearly all organs, tissues and cells. Among them, endothelial cells are amongst the first to be affected and respond to the insult. In this study, we investigated the protective effects of microRNA-30a-5p (miR-30a-5p) on human pulmonary microvascular endothelial cells (HPMECs) treated with lipolysaccharide (LPS). Methods: An in vitro model of sepsis was established in HPMECs with the use of LPS. Transfecting with different tools (mimetic and inhibitor) to modify miR-30a-5p expression. Cell viability, proliferation and apoptosis were detected by the CCK-8 assay, the EdU kit and fluorescence staining, respectively. The autophagy-related protein and mRNA expression, the number of autophagosomes were separately examined through Western blot analysis, qPT-PCR and confocal microscopy. TargetScan and the luciferase reporter assays were used to probe target genes interacting with miR-30a-5p. Results: LPS caused a reduction in the viability and proliferation of HPMECs, as well as an elevation in the number of apoptotic cells. Subsequently, we observed that miR-30a-5p might play a role in preventing LPS-induced inhibition of cell damage and decreasing HPMEC apoptosis, suggesting the potential function of miR-30a-5p in this injury process. Finally, we confirmed that miR-30a-5p exerts its protective effect by regulating cell autophagy, possibly by targeting Beclin-1. Conclusion: Our study provided evidence that autophagy is a crucial aspect in the protective role of miR-30a-5p against LPS-induced HPMEC injury, identifying a promising target for sepsis-related endothelial cell injury.

15 May 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
RPRan Pan
Ran Pan
YSYiyi Sun
Yiyi Sun
LCLu Chen
Lu Chen
JPJianping Pan
Jianping Pan
JGJunping Guo
Junping Guo
Sepsis-associated acute lung injury (S-ALI) remains a life-threatening condition with high mortality and limited therapeutic options. Macrophages, as key sentinels of innate immunity, exhibit remarkable heterogeneity and functional plasticity. These properties are fundamentally driven by metabolic reprogramming, which tailors their effector functions to specific microenvironmental demands. Beyond the traditional M1/M2 binary classification, macrophage activation is now appreciated as a continuous functional spectrum. Pro-inflammatory macrophages preferentially utilize aerobic glycolysis and the pentose phosphate pathway, coupled with suppressed oxidative phosphorylation (OXPHOS), whereas reparative macrophages rely predominantly on OXPHOS and fatty acid oxidation (FAO). Key glycolytic enzymes such as PFKFB3 and PKM2, the transcriptional regulator HIF-1α, and TCA cycle intermediates including succinate and itaconate serve as critical metabolic checkpoints governing macrophage inflammatory responses. During S-ALI, the metabolic landscape undergoes dynamic temporal shifts: the early hyperinflammatory phase is characterized by enhanced glycolysis, while the late immunosuppressive phase exhibits impaired OXPHOS and FAO. This review synthesizes recent advances in understanding how metabolic reprogramming orchestrates macrophage polarization during S-ALI, encompassing glycolysis, the TCA cycle, FAO, and amino acid metabolism. Natural compounds, pharmacological inhibitors, and innovative delivery platforms have shown promise in reprogramming macrophage metabolism to restore immune homeostasis. Notable examples include aerosolized CRISPR/Cas9 nanotherapeutics, biomimetic nanoplatforms, pH-responsive nanoparticles, and engineered exosomes. However, challenges such as broad cytotoxicity, limited macrophage selectivity, incomplete pharmacokinetic characterization, and the timing of intervention in the evolving septic milieu must be addressed. Future strategies should focus on developing cell-type-restricted delivery systems, validating targets in human-relevant models, and designing phase-specific interventions tailored to the metabolic trajectory of S-ALI.

6 November 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
YZYingjie Zhang
Yingjie Zhang
CJChengkang Jin
Chengkang Jin
XXXiao-Ling Xu
Xiao-Ling Xu
JGJunping Guo
Junping Guo
LWLijun Wang
Lijun Wang

11 November 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
RPRan Pan
Ran Pan
JMJiayan Mao
Jiayan Mao
CWCole Wang
Cole Wang
YZYueliang Zheng
Yueliang Zheng
LWLijun Wang
Lijun Wang
JGJunping Guo
Junping Guo
Acute lung injury (ALI) is characterized by damage to alveolar epithelial and capillary endothelial cells, resulting in respiratory failure. The mTOR pathway plays a critical role in the progression of ALI, where its dysregulation leads to excessive autophagy activation and exacerbates cellular injury. Notably, Deptor has been identified as a key endogenous regulator of mTOR signaling. To investigate the role of Deptor in ALI pathogenesis, we used type II alveolar epithelial cell-specific Deptor knockout mice subjected to hemorrhagic shock and intratracheal lipopolysaccharide (LPS) instillation as an in vivo model, and employed LPS-stimulated MLE-12 cells for in vitro mechanistic exploration. Pathological changes, inflammatory responses, apoptosis, and key molecules of the mTOR signaling pathway and autophagy-related proteins were evaluated. Comparative analysis showed that Deptor knockout (Deptor⁻/⁻+ALI) mice exhibited significant alleviation of ALI-associated pathology. Deptor deletion markedly suppressed alveolar epithelial cell apoptosis and restored mTOR signaling. These protective effects were consistently observed in MLE-12 cells following Deptor knockdown. Furthermore, pharmacological inhibition of autophagy by 3‑MA reversed the detrimental effects of Deptor overexpression in LPS‑stimulated MLE-12 cells, reducing apoptosis and improving cell viability. Our study indicate that Deptor is upregulated in ALI and LPS‑stimulated cells, and that its elevation exacerbates injury via mTOR inhibition and autophagy hyperactivation, while its deficiency alleviates ALI by restoring mTOR signaling and limiting excessive autophagy. These results suggest Deptor as a potential therapeutic target for ALI.